JP2017509678A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509678A5 JP2017509678A5 JP2016560724A JP2016560724A JP2017509678A5 JP 2017509678 A5 JP2017509678 A5 JP 2017509678A5 JP 2016560724 A JP2016560724 A JP 2016560724A JP 2016560724 A JP2016560724 A JP 2016560724A JP 2017509678 A5 JP2017509678 A5 JP 2017509678A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- pyrrolidin
- oxy
- pyridyl
- isoindoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 hydroxy, hydroxy Chemical group 0.000 claims 59
- 229910052731 fluorine Inorganic materials 0.000 claims 21
- 239000003112 inhibitor Substances 0.000 claims 20
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 14
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 14
- 229910052801 chlorine Inorganic materials 0.000 claims 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 13
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 239000000556 agonist Substances 0.000 claims 7
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 230000009977 dual effect Effects 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 4
- 102100040918 Pro-glucagon Human genes 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
- 229940044601 receptor agonist Drugs 0.000 claims 3
- 239000000018 receptor agonist Substances 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims 2
- 108010064733 Angiotensins Proteins 0.000 claims 2
- 102000015427 Angiotensins Human genes 0.000 claims 2
- DDHLWKZFVKFDJI-PSDZMVHGSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(NC(N(C2=CC=1)C)C(=O)N(C)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(NC(N(C2=CC=1)C)C(=O)N(C)C)=O)=O DDHLWKZFVKFDJI-PSDZMVHGSA-N 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 claims 2
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 claims 2
- 229940125827 GPR40 agonist Drugs 0.000 claims 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 2
- 102000016267 Leptin Human genes 0.000 claims 2
- 108010092277 Leptin Proteins 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 229940126033 PPAR agonist Drugs 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229940039781 leptin Drugs 0.000 claims 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 2
- KXOXSUKAXXZBJE-UHFFFAOYSA-N n-(1,3-dihydroisoindol-2-yl)acetamide Chemical compound C1=CC=C2CN(NC(=O)C)CC2=C1 KXOXSUKAXXZBJE-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 229940124681 11 beta HSD inhibitor Drugs 0.000 claims 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 claims 1
- FODHWOBAQBTTFS-UHFFFAOYSA-N 3-[4-[2-(2-methylphenyl)ethynyl]phenyl]propanoic acid Chemical compound CC1=CC=CC=C1C#CC1=CC=C(CCC(O)=O)C=C1 FODHWOBAQBTTFS-UHFFFAOYSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 claims 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims 1
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 claims 1
- OULWFCOKAVQGOS-LJQANCHMSA-N 6-[(3R)-3-[6-(cyclopropylmethoxy)pyridin-3-yl]oxy-2-oxopyrrolidin-1-yl]-N,N-dimethyl-4-oxo-3H-quinazoline-2-carboxamide Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(NC(=NC2=CC1)C(=O)N(C)C)=O)=O OULWFCOKAVQGOS-LJQANCHMSA-N 0.000 claims 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 229940121969 Aminopeptidase A inhibitor Drugs 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 101100460776 Arabidopsis thaliana NPY2 gene Proteins 0.000 claims 1
- 101100460782 Arabidopsis thaliana NPY4 gene Proteins 0.000 claims 1
- 101100460788 Arabidopsis thaliana NPY5 gene Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- FDKPKIACHGAHFH-RUZDIDTESA-N C(C)(=O)N1CCN(CC1)C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 Chemical compound C(C)(=O)N1CCN(CC1)C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 FDKPKIACHGAHFH-RUZDIDTESA-N 0.000 claims 1
- XBOQLUBKBMKHTF-LJQANCHMSA-N C(C)(C)(C)N1C(C2=CC(=CC(=C2C1)F)N1C([C@@H](CC1)OC=1C=NC(=CC1)OCC)=O)=O Chemical compound C(C)(C)(C)N1C(C2=CC(=CC(=C2C1)F)N1C([C@@H](CC1)OC=1C=NC(=CC1)OCC)=O)=O XBOQLUBKBMKHTF-LJQANCHMSA-N 0.000 claims 1
- DAMKYSMDVVGCGU-OAQYLSRUSA-N C(C)(C)(C)N1C(C2=CC(=CC(=C2C1)F)N1C([C@@H](CC1)OC=1C=NC(=CC1)OCC1CC1)=O)=O Chemical compound C(C)(C)(C)N1C(C2=CC(=CC(=C2C1)F)N1C([C@@H](CC1)OC=1C=NC(=CC1)OCC1CC1)=O)=O DAMKYSMDVVGCGU-OAQYLSRUSA-N 0.000 claims 1
- AJMIGAHFZFIRIE-JOCHJYFZSA-N C(C)(C)C1=NOC(=N1)C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 Chemical compound C(C)(C)C1=NOC(=N1)C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 AJMIGAHFZFIRIE-JOCHJYFZSA-N 0.000 claims 1
- ALMKOFYMVHNJEV-HXUWFJFHSA-N C(C)(C)SC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound C(C)(C)SC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O ALMKOFYMVHNJEV-HXUWFJFHSA-N 0.000 claims 1
- GLOLUNCPSVKODV-OAQYLSRUSA-N C(C)N1N=NN=C1C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 Chemical compound C(C)N1N=NN=C1C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 GLOLUNCPSVKODV-OAQYLSRUSA-N 0.000 claims 1
- QAHAISUTVRDVAE-GOSISDBHSA-N C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC#N)F)=O Chemical compound C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC#N)F)=O QAHAISUTVRDVAE-GOSISDBHSA-N 0.000 claims 1
- BLCMLIBNFIGMKN-LJQANCHMSA-N C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O Chemical compound C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O BLCMLIBNFIGMKN-LJQANCHMSA-N 0.000 claims 1
- UWDWDLOSHIEAGM-OAQYLSRUSA-N C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(CC)CC)F)=O Chemical compound C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(CC)CC)F)=O UWDWDLOSHIEAGM-OAQYLSRUSA-N 0.000 claims 1
- IDHZHTRQLBAVEI-GOSISDBHSA-N C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)NC)F)=O Chemical compound C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)NC)F)=O IDHZHTRQLBAVEI-GOSISDBHSA-N 0.000 claims 1
- YBZPWYHWJUZHBF-QGZVFWFLSA-N C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)O)F)=O Chemical compound C(C)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)O)F)=O YBZPWYHWJUZHBF-QGZVFWFLSA-N 0.000 claims 1
- FFXOSYUDLRDCHH-HSZRJFAPSA-N C(CCC)(=O)C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 Chemical compound C(CCC)(=O)C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 FFXOSYUDLRDCHH-HSZRJFAPSA-N 0.000 claims 1
- XJWDAUSMMQBPPQ-XMMPIXPASA-N C1(CC1)CC(=O)C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 Chemical compound C1(CC1)CC(=O)C1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 XJWDAUSMMQBPPQ-XMMPIXPASA-N 0.000 claims 1
- QATUUAFKWSXUMD-HSZRJFAPSA-N C1(CC1)CC(=O)C1=CC=C(O[C@H]2C(N(CC2)C=2C=C3C(=NC2)CN(C3=O)CC(=O)N(C)C)=O)C=C1 Chemical compound C1(CC1)CC(=O)C1=CC=C(O[C@H]2C(N(CC2)C=2C=C3C(=NC2)CN(C3=O)CC(=O)N(C)C)=O)C=C1 QATUUAFKWSXUMD-HSZRJFAPSA-N 0.000 claims 1
- YJBGAEPWPUPCLU-XMMPIXPASA-N C1(CC1)CCCC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound C1(CC1)CCCC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O YJBGAEPWPUPCLU-XMMPIXPASA-N 0.000 claims 1
- OZAYHIDPQJHLIW-JOCHJYFZSA-N C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)C(C)C)F)=O Chemical compound C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)C(C)C)F)=O OZAYHIDPQJHLIW-JOCHJYFZSA-N 0.000 claims 1
- ZKROFISXVDIESG-HXUWFJFHSA-N C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)C)F)=O Chemical compound C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)C)F)=O ZKROFISXVDIESG-HXUWFJFHSA-N 0.000 claims 1
- ARLWECBJKCWZPN-JOCHJYFZSA-N C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O Chemical compound C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O ARLWECBJKCWZPN-JOCHJYFZSA-N 0.000 claims 1
- KORDPXKLTKTVTD-OAQYLSRUSA-N C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)NC)F)=O Chemical compound C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)NC)F)=O KORDPXKLTKTVTD-OAQYLSRUSA-N 0.000 claims 1
- PQBYUYHIXLNXSD-HSZRJFAPSA-N C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC1(COC1)C)F)=O Chemical compound C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC1(COC1)C)F)=O PQBYUYHIXLNXSD-HSZRJFAPSA-N 0.000 claims 1
- AJGSPUKJYPITMZ-JOCHJYFZSA-N C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CCCO)F)=O Chemical compound C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CCCO)F)=O AJGSPUKJYPITMZ-JOCHJYFZSA-N 0.000 claims 1
- AZAIYPRABFICAW-JOCHJYFZSA-N C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound C1(CC1)CCOC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O AZAIYPRABFICAW-JOCHJYFZSA-N 0.000 claims 1
- UEVYZPPOSIIICV-OAQYLSRUSA-N C1(CC1)CNC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound C1(CC1)CNC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O UEVYZPPOSIIICV-OAQYLSRUSA-N 0.000 claims 1
- UMJCQGZYVREIFE-JOCHJYFZSA-N C1(CC1)COC1=C(C=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O)C Chemical compound C1(CC1)COC1=C(C=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O)C UMJCQGZYVREIFE-JOCHJYFZSA-N 0.000 claims 1
- XXYZRIBMCHYURF-OAQYLSRUSA-N C1(CC1)COC1=C(C=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O)F Chemical compound C1(CC1)COC1=C(C=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O)F XXYZRIBMCHYURF-OAQYLSRUSA-N 0.000 claims 1
- HEOLYRRICYVZKH-NRFANRHFSA-N C1(CC1)COC1=CC=C(C=N1)O[C@@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O HEOLYRRICYVZKH-NRFANRHFSA-N 0.000 claims 1
- IGYOYFIYQKZMSA-NRFANRHFSA-N C1(CC1)COC1=CC=C(C=N1)O[C@@H]1C(N(CC1)C=1C=C2C(N(N(C2=CC1)C)CC(=O)N(C)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@@H]1C(N(CC1)C=1C=C2C(N(N(C2=CC1)C)CC(=O)N(C)C)=O)=O IGYOYFIYQKZMSA-NRFANRHFSA-N 0.000 claims 1
- YNCHEOBDEHOPBY-LJQANCHMSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)C)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)C)F)=O YNCHEOBDEHOPBY-LJQANCHMSA-N 0.000 claims 1
- BIGOOMZSVCDOEQ-OAQYLSRUSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O BIGOOMZSVCDOEQ-OAQYLSRUSA-N 0.000 claims 1
- FUAXLZPLKFBZEC-XMMPIXPASA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N1CCC(CC1)O)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N1CCC(CC1)O)F)=O FUAXLZPLKFBZEC-XMMPIXPASA-N 0.000 claims 1
- BOKAEFASFVXZER-HXUWFJFHSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC=1N=NN(N1)C)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC=1N=NN(N1)C)F)=O BOKAEFASFVXZER-HXUWFJFHSA-N 0.000 claims 1
- DHMZHRZEBPAISE-HXUWFJFHSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CS(=O)(=O)C)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CS(=O)(=O)C)F)=O DHMZHRZEBPAISE-HXUWFJFHSA-N 0.000 claims 1
- KMGNUWCOHXXCPO-SMAGUSHISA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CS(=O)C)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CS(=O)C)F)=O KMGNUWCOHXXCPO-SMAGUSHISA-N 0.000 claims 1
- AAASVBPEJVSXHW-HXUWFJFHSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CSC)F)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CSC)F)=O AAASVBPEJVSXHW-HXUWFJFHSA-N 0.000 claims 1
- RBKKXQGMALNCHF-YBMSBYLISA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)C(C(=O)O)C)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)C(C(=O)O)C)=O RBKKXQGMALNCHF-YBMSBYLISA-N 0.000 claims 1
- HEOLYRRICYVZKH-OAQYLSRUSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O HEOLYRRICYVZKH-OAQYLSRUSA-N 0.000 claims 1
- NLHKJMZAFUJLRK-JOCHJYFZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N1CC(C1)O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N1CC(C1)O)=O NLHKJMZAFUJLRK-JOCHJYFZSA-N 0.000 claims 1
- GEZXYZWXMSMYIF-HXUWFJFHSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)NC)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)NC)=O GEZXYZWXMSMYIF-HXUWFJFHSA-N 0.000 claims 1
- HNVJZACHLHTHBR-OAQYLSRUSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CCC)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CCC)=O HNVJZACHLHTHBR-OAQYLSRUSA-N 0.000 claims 1
- DVKLCAKOMYMDND-HXUWFJFHSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(=NC2=CC1)C(=O)N(C)C)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(=NC2=CC1)C(=O)N(C)C)C)=O)=O DVKLCAKOMYMDND-HXUWFJFHSA-N 0.000 claims 1
- ZKWWRWQIXAJHPK-JOCHJYFZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)(C)C)CC(=O)N(C)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)(C)C)CC(=O)N(C)C)=O)=O ZKWWRWQIXAJHPK-JOCHJYFZSA-N 0.000 claims 1
- HHCUFCSKVXDCSG-VXNXSFHZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)C)CC(=O)N(C)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)C)CC(=O)N(C)C)=O)=O HHCUFCSKVXDCSG-VXNXSFHZSA-N 0.000 claims 1
- WEAGSKPQNHGGEI-YBMSBYLISA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)C)CC(=O)O)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)C)CC(=O)O)=O)=O WEAGSKPQNHGGEI-YBMSBYLISA-N 0.000 claims 1
- NEPSTHKXVYGUBJ-FOIFJWKZSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)CC(=O)N(C)C)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)CC(=O)N(C)C)C)=O)=O NEPSTHKXVYGUBJ-FOIFJWKZSA-N 0.000 claims 1
- XMWZAUMIYDATDM-GFOWMXPYSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)CC(=O)O)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(C(C2=CC1)CC(=O)O)C)=O)=O XMWZAUMIYDATDM-GFOWMXPYSA-N 0.000 claims 1
- IGYOYFIYQKZMSA-OAQYLSRUSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(N(C2=CC1)C)CC(=O)N(C)C)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(N(N(C2=CC1)C)CC(=O)N(C)C)=O)=O IGYOYFIYQKZMSA-OAQYLSRUSA-N 0.000 claims 1
- LIYHJQTVNZTTSA-QGZVFWFLSA-N C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(NNC2=CC1)=O)=O Chemical compound C1(CC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C=1C=C2C(NNC2=CC1)=O)=O LIYHJQTVNZTTSA-QGZVFWFLSA-N 0.000 claims 1
- HCWZNFMIIZXTCY-HXUWFJFHSA-N C1(CC1)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O Chemical compound C1(CC1)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O HCWZNFMIIZXTCY-HXUWFJFHSA-N 0.000 claims 1
- UQXZVJCTWXZLCW-HXUWFJFHSA-N C1(CC1)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound C1(CC1)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O UQXZVJCTWXZLCW-HXUWFJFHSA-N 0.000 claims 1
- SOIDDKGLBQZHSW-LJQANCHMSA-N C1(CC1)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)OC)=O Chemical compound C1(CC1)OC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)OC)=O SOIDDKGLBQZHSW-LJQANCHMSA-N 0.000 claims 1
- RNRFFCNLQLSZER-HXUWFJFHSA-N C1(CC1)SC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound C1(CC1)SC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O RNRFFCNLQLSZER-HXUWFJFHSA-N 0.000 claims 1
- MEWYBQBOZPLSNC-JOCHJYFZSA-N C1(CCC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O Chemical compound C1(CCC1)COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O MEWYBQBOZPLSNC-JOCHJYFZSA-N 0.000 claims 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims 1
- IQLXRBFDGGBIKF-OAQYLSRUSA-N CC(COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O)(C)C Chemical compound CC(COC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC(=C2CN(C(C2=C1)=O)CC(=O)N(C)C)F)=O)(C)C IQLXRBFDGGBIKF-OAQYLSRUSA-N 0.000 claims 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 claims 1
- UKTBICBBZMTXDL-QGZVFWFLSA-N ClC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound ClC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O UKTBICBBZMTXDL-QGZVFWFLSA-N 0.000 claims 1
- QDYULXCRJJIWFF-LJQANCHMSA-N ClC=1C=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=CC=1OC(F)(F)F Chemical compound ClC=1C=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=CC=1OC(F)(F)F QDYULXCRJJIWFF-LJQANCHMSA-N 0.000 claims 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 claims 1
- 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 claims 1
- 229940097420 Diuretic Drugs 0.000 claims 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 102400000686 Endothelin-1 Human genes 0.000 claims 1
- 101800004490 Endothelin-1 Proteins 0.000 claims 1
- LCDDAGSJHKEABN-MLGOLLRUSA-N Evogliptin Chemical compound C1CNC(=O)[C@@H](COC(C)(C)C)N1C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F LCDDAGSJHKEABN-MLGOLLRUSA-N 0.000 claims 1
- XGKSGUNULDSZNJ-HSZRJFAPSA-N FC1=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=CC(=C1)F Chemical compound FC1=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=CC(=C1)F XGKSGUNULDSZNJ-HSZRJFAPSA-N 0.000 claims 1
- QSMIPPJJEHNBRF-GOSISDBHSA-N FC1=C2CN(C(C2=CC(=C1)N1C([C@@H](CC1)OC=1C=NC(=CC1)OCC(F)(F)F)=O)=O)CC(=O)N(C)C Chemical compound FC1=C2CN(C(C2=CC(=C1)N1C([C@@H](CC1)OC=1C=NC(=CC1)OCC(F)(F)F)=O)=O)CC(=O)N(C)C QSMIPPJJEHNBRF-GOSISDBHSA-N 0.000 claims 1
- SUWPEBVOKUVCRH-RUZDIDTESA-N FC1=CC=C(C(=O)C2=CC=C(O[C@H]3C(N(CC3)C3=CC=C4CN(C(C4=C3)=O)CC(=O)N(C)C)=O)C=C2)C=C1 Chemical compound FC1=CC=C(C(=O)C2=CC=C(O[C@H]3C(N(CC3)C3=CC=C4CN(C(C4=C3)=O)CC(=O)N(C)C)=O)C=C2)C=C1 SUWPEBVOKUVCRH-RUZDIDTESA-N 0.000 claims 1
- URNYFEXDRLOQHK-QGZVFWFLSA-N FC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O Chemical compound FC1=CC=C(C=N1)O[C@H]1C(N(CC1)C1=CC=C2CN(C(C2=C1)=O)CC(=O)N(C)C)=O URNYFEXDRLOQHK-QGZVFWFLSA-N 0.000 claims 1
- XWEJZKZGLJKNDY-HSZRJFAPSA-N FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 Chemical compound FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 XWEJZKZGLJKNDY-HSZRJFAPSA-N 0.000 claims 1
- ZNKLXAYSTWNLCD-XMMPIXPASA-N FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)CCO)=O)C=C1 Chemical compound FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)CCO)=O)C=C1 ZNKLXAYSTWNLCD-XMMPIXPASA-N 0.000 claims 1
- JFLIWMFHGOLBTR-XMMPIXPASA-N FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N2CC(C2)O)=O)C=C1 Chemical compound FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N2CC(C2)O)=O)C=C1 JFLIWMFHGOLBTR-XMMPIXPASA-N 0.000 claims 1
- YEIBZVIXCBYXSG-AREMUKBSSA-N FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N2CCC(CC2)O)=O)C=C1 Chemical compound FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N2CCC(CC2)O)=O)C=C1 YEIBZVIXCBYXSG-AREMUKBSSA-N 0.000 claims 1
- FCULNINMIHPLOH-JOCHJYFZSA-N FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C=2C=C3C(=NC2)CN(C3=O)CC(=O)N(C)C)=O)C=C1 Chemical compound FC1=CC=C(OC2=CC=C(C=N2)O[C@H]2C(N(CC2)C=2C=C3C(=NC2)CN(C3=O)CC(=O)N(C)C)=O)C=C1 FCULNINMIHPLOH-JOCHJYFZSA-N 0.000 claims 1
- QRDYUMLUUBFUJG-RUZDIDTESA-N FC1=CC=C(OC2=CC=C(O[C@H]3C(N(CC3)C3=CC=C4CN(C(C4=C3)=O)CC(=O)N(C)C)=O)C=C2)C=C1 Chemical compound FC1=CC=C(OC2=CC=C(O[C@H]3C(N(CC3)C3=CC=C4CN(C(C4=C3)=O)CC(=O)N(C)C)=O)C=C2)C=C1 QRDYUMLUUBFUJG-RUZDIDTESA-N 0.000 claims 1
- VHRUDAVHWDWRJC-LJQANCHMSA-N FC1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 Chemical compound FC1=CC=C(O[C@H]2C(N(CC2)C2=CC=C3CN(C(C3=C2)=O)CC(=O)N(C)C)=O)C=C1 VHRUDAVHWDWRJC-LJQANCHMSA-N 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 claims 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 claims 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 claims 1
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 claims 1
- 229940100607 GPR119 agonist Drugs 0.000 claims 1
- 229940123483 GPR142 agonist Drugs 0.000 claims 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 claims 1
- 206010071602 Genetic polymorphism Diseases 0.000 claims 1
- 101800001586 Ghrelin Proteins 0.000 claims 1
- 102400000442 Ghrelin-28 Human genes 0.000 claims 1
- 108010063919 Glucagon Receptors Proteins 0.000 claims 1
- 102100040890 Glucagon receptor Human genes 0.000 claims 1
- 229940123232 Glucagon receptor agonist Drugs 0.000 claims 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 claims 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims 1
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 claims 1
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 claims 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 claims 1
- 101710125793 Hydroxycarboxylic acid receptor 2 Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 229940125922 IBAT inhibitor Drugs 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims 1
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 101150111774 NPY5R gene Proteins 0.000 claims 1
- NTVWJGLFFQEHII-OAQYLSRUSA-N OC1CCN(CC1)C(CN1C(C2=CC(=CC=C2C1)N1C([C@@H](CC1)OC=1C=NC(=CC1)OCC(F)(F)F)=O)=O)=O Chemical compound OC1CCN(CC1)C(CN1C(C2=CC(=CC=C2C1)N1C([C@@H](CC1)OC=1C=NC(=CC1)OCC(F)(F)F)=O)=O)=O NTVWJGLFFQEHII-OAQYLSRUSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims 1
- 101710176384 Peptide 1 Proteins 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 claims 1
- 102000013272 Renalase Human genes 0.000 claims 1
- 108010090629 Renalase Proteins 0.000 claims 1
- 108090000783 Renin Proteins 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 108091006300 SLC2A4 Proteins 0.000 claims 1
- 229940123451 Somatostatin receptor 3 agonist Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 229940123876 Thyroid hormone receptor beta agonist Drugs 0.000 claims 1
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 claims 1
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 claims 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims 1
- 101710204865 Tyrosine-protein phosphatase 1 Proteins 0.000 claims 1
- 102400000752 Xenin Human genes 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 239000002170 aldosterone antagonist Substances 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 229960001667 alogliptin Drugs 0.000 claims 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 229950009977 anagliptin Drugs 0.000 claims 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229960001713 canagliflozin Drugs 0.000 claims 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 claims 1
- 229960003834 dapagliflozin Drugs 0.000 claims 1
- 238000006356 dehydrogenation reaction Methods 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940125542 dual agonist Drugs 0.000 claims 1
- 229940125436 dual inhibitor Drugs 0.000 claims 1
- 229950003693 dutogliptin Drugs 0.000 claims 1
- 229960003345 empagliflozin Drugs 0.000 claims 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 229950011259 evogliptin Drugs 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 1
- 229960002458 gemigliptin Drugs 0.000 claims 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 1
- 229940124828 glucokinase activator Drugs 0.000 claims 1
- 230000036252 glycation Effects 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- 229950000991 ipragliflozin Drugs 0.000 claims 1
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 claims 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 claims 1
- 229960002397 linagliptin Drugs 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 239000002395 mineralocorticoid Substances 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 claims 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000016670 prohibitin Human genes 0.000 claims 1
- 108010028138 prohibitin Proteins 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 229940126844 remogliflozin Drugs 0.000 claims 1
- 229950011516 remogliflozin etabonate Drugs 0.000 claims 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960004937 saxagliptin Drugs 0.000 claims 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 1
- 108010033693 saxagliptin Proteins 0.000 claims 1
- 229940126842 sergliflozin Drugs 0.000 claims 1
- HFLCZNNDZKKXCS-OUUBHVDSSA-N sergliflozin Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HFLCZNNDZKKXCS-OUUBHVDSSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229950000034 teneligliptin Drugs 0.000 claims 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 229950006667 tofogliflozin Drugs 0.000 claims 1
- 239000003174 triple reuptake inhibitor Substances 0.000 claims 1
- 229960001254 vildagliptin Drugs 0.000 claims 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 1
- IDHVLSACPFUBDY-QCDLPZBNSA-N xenin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CN=CN1 IDHVLSACPFUBDY-QCDLPZBNSA-N 0.000 claims 1
- 108010006643 xenin 25 Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305496.3 | 2014-04-04 | ||
| EP14305496 | 2014-04-04 | ||
| PCT/EP2015/057415 WO2015150565A1 (en) | 2014-04-04 | 2015-04-02 | Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017509678A JP2017509678A (ja) | 2017-04-06 |
| JP2017509678A5 true JP2017509678A5 (https=) | 2018-05-17 |
Family
ID=50513860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016560724A Abandoned JP2017509678A (ja) | 2014-04-04 | 2015-04-02 | 糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしてのイソインドリノン化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9908868B2 (https=) |
| EP (1) | EP3126350B1 (https=) |
| JP (1) | JP2017509678A (https=) |
| KR (1) | KR20160132415A (https=) |
| CN (1) | CN106164068A (https=) |
| AR (1) | AR099937A1 (https=) |
| AU (1) | AU2015239022A1 (https=) |
| CA (1) | CA2943864A1 (https=) |
| CL (1) | CL2016002498A1 (https=) |
| DO (1) | DOP2016000226A (https=) |
| EA (1) | EA201692007A1 (https=) |
| EC (1) | ECSP16078782A (https=) |
| IL (1) | IL248130A0 (https=) |
| MA (1) | MA39359A1 (https=) |
| MX (1) | MX2016013037A (https=) |
| PE (1) | PE20170333A1 (https=) |
| PH (1) | PH12016501724A1 (https=) |
| SG (1) | SG11201607247TA (https=) |
| TW (1) | TW201623286A (https=) |
| WO (1) | WO2015150565A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| RS60017B1 (sr) | 2014-04-04 | 2020-04-30 | H Lundbeck As | Halogenovani kvinazolin-thf-amini kao pde1 inhibitori |
| CN105399744B (zh) * | 2015-12-17 | 2017-07-18 | 黄燕鸽 | 一种奥格列汀的合成方法 |
| WO2018049324A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Monocyclic compounds useful as gpr120 modulators |
| EP3509588B1 (en) * | 2016-09-12 | 2023-06-07 | Integral Health,Inc. | Bicyclic compounds useful as gpr120 modulators |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| AR110988A1 (es) | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| WO2018170067A1 (en) * | 2017-03-14 | 2018-09-20 | Dana-Farber Cancer Institute, Inc. | Small molecule sensitization of bax activation for induction of cell death |
| IT201700039562A1 (it) * | 2017-04-10 | 2018-10-10 | Univ Pisa | Derivati isoindolinici quali attivatori di ampk |
| TWI714231B (zh) * | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| KR102289381B1 (ko) * | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN117164597B (zh) * | 2023-11-02 | 2024-02-09 | 深圳创元生物医药科技有限公司 | 一种smtp-0合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638932A1 (en) | 2003-06-18 | 2006-03-29 | Pfizer Products Inc. | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams |
| TWI389897B (zh) * | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AU2011256455A1 (en) * | 2010-05-17 | 2013-01-10 | Array Biopharma Inc. | Piperidinyl-substituted lactams as GPR119 modulators |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| US20130184257A1 (en) | 2010-09-17 | 2013-07-18 | Thomas Daniel Aicher | Piperidinyl-substituted lactams as gpr119 modulators |
| CA2853784A1 (en) | 2011-11-11 | 2013-05-16 | Glaxosmithkline Llc | Treatment of blood lipid abnormalities and other conditions |
| AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
-
2015
- 2015-04-01 AR ARP150100990A patent/AR099937A1/es unknown
- 2015-04-01 TW TW104110614A patent/TW201623286A/zh unknown
- 2015-04-02 MX MX2016013037A patent/MX2016013037A/es unknown
- 2015-04-02 AU AU2015239022A patent/AU2015239022A1/en not_active Abandoned
- 2015-04-02 EP EP15714502.0A patent/EP3126350B1/en active Active
- 2015-04-02 CA CA2943864A patent/CA2943864A1/en not_active Abandoned
- 2015-04-02 WO PCT/EP2015/057415 patent/WO2015150565A1/en not_active Ceased
- 2015-04-02 MA MA39359A patent/MA39359A1/fr unknown
- 2015-04-02 SG SG11201607247TA patent/SG11201607247TA/en unknown
- 2015-04-02 PE PE2016001893A patent/PE20170333A1/es not_active Application Discontinuation
- 2015-04-02 EA EA201692007A patent/EA201692007A1/ru unknown
- 2015-04-02 KR KR1020167026832A patent/KR20160132415A/ko not_active Withdrawn
- 2015-04-02 CN CN201580017439.8A patent/CN106164068A/zh active Pending
- 2015-04-02 JP JP2016560724A patent/JP2017509678A/ja not_active Abandoned
-
2016
- 2016-08-29 DO DO2016000226A patent/DOP2016000226A/es unknown
- 2016-09-01 PH PH12016501724A patent/PH12016501724A1/en unknown
- 2016-09-29 IL IL248130A patent/IL248130A0/en unknown
- 2016-09-30 CL CL2016002498A patent/CL2016002498A1/es unknown
- 2016-10-03 US US15/284,334 patent/US9908868B2/en not_active Expired - Fee Related
- 2016-10-04 EC ECIEPI201678782A patent/ECSP16078782A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509678A5 (https=) | ||
| JP2017515797A5 (https=) | ||
| US10428076B2 (en) | Soluble guanylate cyclase stimulators | |
| JP2017509679A5 (https=) | ||
| US11535630B2 (en) | Apelin receptor (APJ) agonists and uses thereof | |
| US9777002B2 (en) | Inhibitors of the renal outer medullary potassium channel | |
| JP2017509678A (ja) | 糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしてのイソインドリノン化合物 | |
| US20130023494A1 (en) | Modulators of the gpr119 receptor and the treatment of disorders related thereto | |
| TW202019950A (zh) | Pcsk9拮抗劑化合物 | |
| US12448384B2 (en) | Diacylglyceride O-acyltransferase 2 inhibitors | |
| US11104690B2 (en) | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | |
| EP3585775A1 (en) | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
| JP2014505689A (ja) | 代謝障害の処置用ｂａｃｅ−２阻害剤 | |
| US9951052B2 (en) | Inhibitors of the renal outer medullary potassium channel | |
| JP2017515797A (ja) | 糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての置換インダノン化合物 | |
| US20170275274A1 (en) | Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 | |
| JP2013537242A5 (https=) | ||
| WO2010107610A1 (en) | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds | |
| US11976061B2 (en) | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | |
| JP2023541714A (ja) | 新規なジアシルグリセリドｏ－アシルトランスフェラーゼ２阻害剤としてのオキシインドール誘導体の製造 | |
| US12540132B2 (en) | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | |
| US20240254114A1 (en) | Preparation of fused azole derivatives as novel diacylglyceride 0-acyltransferase 2 inhibitors | |
| CN102166357A (zh) | 包含双环氮杂烷类衍生物的药物组合物 |